Interchangeability between SP263 and 22C3 assays in lung cancer specimens: a reality in daily practice

被引：0
|
作者：
Jang, Min Hye [1 ]
Baek, Jina [2 ]
Shin, Kyeong-Cheol [2 ]
Lee, Jang Hoon [2 ]
机构：
[1] Yeungnam Univ Hosp, Daegu, South Korea
[2] Yeungnam Univ, Sch Med, Daegu, South Korea
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1841
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
    Ahn, Soomin
    Kim, Kyoung-Mee
    MODERN PATHOLOGY, 2021, 34 (09) : 1719 - 1727
  • [32] Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
    Haipeng Xu
    Gen Lin
    Cheng Huang
    Weifeng Zhu
    Qian Miao
    Xirong Fan
    Biao Wu
    Xiaobing Zheng
    Xiandong Lin
    Kan Jiang
    Dan Hu
    Chao Li
    Scientific Reports, 7
  • [33] Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
    Xu, Haipeng
    Lin, Gen
    Huang, Cheng
    Zhu, Weifeng
    Miao, Qian
    Fan, Xirong
    Wu, Biao
    Zheng, Xiaobing
    Lin, Xiandong
    Jiang, Kan
    Hu, Dan
    Li, Chao
    SCIENTIFIC REPORTS, 2017, 7
  • [34] Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
    Herbst, R. S.
    de Marinis, F.
    Giaccone, G.
    Reinmuth, N.
    Vergnenegre, A.
    Barrios, C. H.
    Morise, M.
    Felip, E.
    Andric, Z.
    Geater, S.
    Ozguroglu, M.
    Mocci, S.
    McCleland, M.
    Zou, W.
    Enquist, I.
    Komatsubara, K.
    Deng, Y.
    Kuriki, H.
    Spigel, D. R.
    Jassem, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 62 - 63
  • [35] A multicentric Portuguese study for the assessment of PD-L1 score in NSCLC using 22C3 and SP263 clones on Ventana's platform: a stepping stone for the IVDR legislation landscape?
    Sousa, V.
    Luis, A.
    Ribeiro, A.
    Souto de Moura, C.
    Rolim, I.
    Cunha, A. L.
    Quintana, C.
    Eloy, C.
    Pinto, E.
    Cunha, F.
    Correia-Pinto, J.
    Carvalho, L.
    Vizcaino, J.
    Coelho, C.
    Ferreira Carlos, F.
    Borralho, P.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S152 - S153
  • [36] 抗体22C3与SP263检测非小细胞肺癌标本PD-L1水平的一致性比较
    王葆强
    邵琼怡
    孙波
    中国民康医学, 2023, 35 (04) : 138 - 140
  • [37] A Comparative Study of the PD-L1 IHC 22C3 and 28-8 Assays on Lung Cancer Samples
    Krigsfeld, G. S.
    Zerba, K.
    Novotny, J., Jr.
    Chizhevsky, V.
    Ragheb, J. W.
    White, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 236 - 237
  • [38] Concordance of tumor and immune cell staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 tests in NSCLC patient samples.
    Scott, Marietta
    Ratcliffe, Marianne J.
    Sharpe, Alan
    Barker, Craig
    Scorer, Paul
    Rebelatto, Marlon
    Al-Masri, Hytham
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [39] PD-L1 IHC 22C3 pharmDx: Analytical validation on cervical cancer specimens
    Musser, J.
    Evans, T.
    Posch, A.
    Vasquez, J.
    Tabuena-Frolli, S.
    Apostolaki, A.
    Kulangara, K.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S109 - S109
  • [40] Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer
    Miyakoshi, Jun
    Yazaki, Shu
    Shimoi, Tatsunori
    Onishi, Mai
    Saito, Ayumi
    Kita, Shosuke
    Yamamoto, Kasumi
    Kojima, Yuki
    Sumiyoshi-Okuma, Hitomi
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Murata, Takeshi
    Shiino, Sho
    Takayama, Shin
    Suto, Akihiko
    Fujiwara, Yasuhiro
    Yoshida, Masayuki
    Yonemori, Kan
    VIRCHOWS ARCHIV, 2023, 483 (06) : 855 - 863
12345